Combination of <i>KIT</i> and <i>FLT3‐</i> ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission-Reference-Cited by-同舟云学术

Combination of KIT and FLT3‐ ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission

Published:2022-05-15 Issue:4 Volume:40 Page:724-733
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Wang Jun¹,Dao Feng‐Ting¹,Wang Yu¹^ORCID,Jiang Hao¹,Xu Lan‐Ping¹,Zhao Xiao‐Su¹,Zhang Xiao‐Hui¹,Liu Kai‐Yan¹,Huang Xiao‐Jun¹,Jiang Qian¹,Qin Ya‐Zhen¹^ORCID

Affiliation:

1. Peking University People's Hospital Peking University Institute of Hematology National Clinical Research Center for Hematologic Disease Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation Beijing China

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.3015

Reference31 articles.

1. The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial

2. NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G‐CSF based regimens;American Journal of Hematology;2022-12-24

2. EXABS-150-AML Is MRD More Prognostic than Initial Presentation Characteristics in AML Patients?;Clinical Lymphoma Myeloma and Leukemia;2022-10